29 completed, 10 terminated, 4 recruiting, 2 withdrawn. 26 Phase 1, 18 Phase 2, 7 Phase 3, 2 Not applicable.
Follow AVEO Pharmaceuticals, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| OLE Study Subsequent to Parent Study of Rilogrotug for the Treatment of Weight Loss and Anorexia in Patients With Cancer Cachexia and mCRC or mNSCLC Rilogrotug - Cachexia; Cancer, Cachexia | Phase 2 / Phase 3 | Not yet recruiting | AVEO Pharmaceuticals, Inc. | 400 | 2027-02-01 | 2026-10-22 |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma Ficlatuzumab, Cetuximab, Placebo - Metastatic Head-and-neck Squamous-cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma | Phase 3 | Recruiting | AVEO Pharmaceuticals, Inc. | 410 | 2024-01-11 | 2026-04-09 |
| Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 48 | 2024-01-05 | 2026-10-07 |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia AV-380 - Cachexia | Phase 1 | Recruiting | AVEO Pharmaceuticals, Inc. | 30 | 2023-06-13 | 2026-01-08 |
| Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Tivozanib, Nivolumab - Renal Cell Carcinoma | Phase 3 | Completed | AVEO Pharmaceuticals, Inc. | 343 | 2021-09-09 | 2026-05-08 |
| A Phase 1 Study of AV-380 in Healthy Subjects AV-380, Placebo - Cachexia | Phase 1 | Completed | AVEO Pharmaceuticals, Inc. | 51 | 2021-02-22 | 2023-06-12 |
| A Study of Ficlatuzumab With HiDAC and HiDAC Alone in Adults With Relapsed or Refractory Acute Myeloid Leukemia Ficlatuzumab, Cytarabine - Acute Myeloid Leukemia | Phase 2 | Withdrawn | AVEO Pharmaceuticals, Inc. | 2020-01-31 | 2020-03-31 | |
| A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma Tivozanib, Durvalumab - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 27 | 2019-09-30 | 2023-07-12 |
| Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer Gemcitabine, Nab-paclitaxel, Ficlatuzumab - Pancreatic Cancer | Phase 1 | Completed | Dana-Farber Cancer Institute | 26 | 2018-01-17 | 2021-08-03 |
| Phase 1/2 Study of Tivozanib in Combination With Nivolumab in Subjects With RCC Tivozanib, Nivolumab - Carcinoma, Renal Cell | Phase 1 / Phase 2 | Completed | AVEO Pharmaceuticals, Inc. | 28 | 2017-03-22 | 2021-12-06 |
| Study of Biomarker-Based Treatment of Acute Myeloid Leukemia Samalizumab (BAML-16-001-S1), BI 836858 (BAML-16-001-S2), Laboratory Biomarker Analysis - Previously Untreated Relapsed Refractory Acute Myeloid Leukemia | Phase 2 / Phase 3 | Recruiting | Beat AML, LLC | 3000 | 2016-11-01 | 2026-09-03 |
| A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) Tivozanib hydrochloride, Sorafenib - Carcinoma, Renal Cell | Phase 3 | Completed | AVEO Pharmaceuticals, Inc. | 350 | 2016-05-24 | 2023-07-18 |
| Ficlatuzumab, Cisplatin and IMRT in Locally Advanced Head and Neck Squamous Cell Carcinoma Ficlatuzumab, Cisplatin, Intensity Modulated Radiotherapy (IMRT) - Carcinoma, Squamous Cell of Head and Neck | Phase 1 | Terminated | Julie E. Bauman, MD, MPH | 1 | 2015-09-01 | 2017-11-13 |
| Ficlatuzumab and Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Ficlatuzumab, Cetuximab - Carcinoma, Squamous Cell of Head and Neck, Squamous Cell Carcinoma of the Head and Neck | Phase 1 | Completed | James J Lee | 14 | 2015-08-01 | 2019-04-18 |
| Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML Ficlatuzumab, Cytarabine - Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia | Phase 1 | Terminated | C. Babis Andreadis | 17 | 2015-05-01 | 2020-03-24 |
| A Phase 2, Study of Ficlatuzumab Plus Erlotinib vs. Placebo Plus Erlotinib in Subjects With Previously Untreated Metastatic, EGFR-mutated NSCLC and BDX004 Positive Label Ficlatuzumab, Erlotinib, placebo - Non-small Cell Lung Cancer | Phase 2 | Terminated | AVEO Pharmaceuticals, Inc. | 10 | 2014-11-01 | 2020-10-22 |
| Tivozanib As Maintenance Therapy In GYN Tivozanib - Ovarian Cancer, Fallopian Tube Cancer | Phase 2 | Terminated | Dana-Farber Cancer Institute | 4 | 2013-11-01 | 2017-06-05 |
| Tivozanib in Treating Patients With Liver Cancer That Is Metastatic or Cannot Be Removed by Surgery Tivozanib (1mg), Tivozanib (1.5mg) - Advanced Adult Hepatocellular Carcinoma, Non-Resectable Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Roswell Park Cancer Institute | 33 | 2013-07-11 | 2020-10-28 |
| Tivozanib Before Surgery in Treating Patients With Localized Kidney Cancer tivozanib, therapeutic conventional surgery - Stage II Renal Cell Cancer, Stage III Renal Cell Cancer | Not applicable | Withdrawn | Roswell Park Cancer Institute | 2013-03-14 | 2022-08-15 | |
| A Phase II Study of Tivozanib in Patients With Metastatic and Non-resectable Soft Tissue Sarcomas tivozanib, laboratory biomarker analysis - Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma | Phase 2 | Completed | Northwestern University | 58 | 2013-03-06 | 2019-09-09 |
Showing 20 of 47. Sign in to see all of them.
Carcinoma, Renal Cell (9) · Neoplasms (6) · Colorectal Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (4) · Cachexia (3) · Squamous Cell Carcinoma of Head and Neck (3) · Breast Neoplasms (2) · Carcinoma (2) · Gastrointestinal Neoplasms (2) · Leukemia, Myeloid, Acute (2) · Liver Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Anorexia (1)
tivozanib (27) · ficlatuzumab (12) · Cytarabine (3) · Nivolumab (3) · Paclitaxel (3) · Sorafenib (3) · Capecitabine (2) · Cetuximab (2) · Erlotinib Hydrochloride (2) · MP 412 (2) · temsirolimus (2) · 130-nm albumin-bound paclitaxel (1) · 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo(1,2-a)pyrazin-8-amine (1) · AV-203 (1) · AZD5153 (1)
United States (39) · Canada (9) · Italy (9) · France (7) · Spain (7) · United Kingdom (7) · Czechia (6) · Germany (6) · Australia (5) · Belgium (5) · Hungary (5) · Poland (5) · Ukraine (5) · India (4) · Netherlands (4)
Joshua Zhang, M.D. (2) · Philip Komarnitsky, MD (2) · Robert J. Motzer, MD (2) · Alice Mims, MD (1) · Anna Berkenblit, MD (1) · Bassel El-Rayes, MD (1) · Brian Wolpin, MD (1) · Carmen S. Puparelli, MD (1) · Chao Huang, MD (1) · Charalambos Andreadis, MD (1) · Dennis Vargo, MD (1) · Dmitriy G Nosov, M.D. (1) · Eric Jonasch, M D (1)
PMID 23580238, PMID 23726267, PMID 25591799, PMID 27771610, PMID 29346833, PMID 31810797, PMID 32037403, PMID 33010459, PMID 33101775, PMID 33445053, PMID 33980467, PMID 34071188, PMID 35304832, PMID 36576430, PMID 36912078, PMID 37146227, PMID 37185961, PMID 37315114, PMID 38262444, PMID 39284329, PMID 40504618, PMID 40557912
2009 (1), P30CA016056 (1)